{"commentary":{"count":179,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":92,"podcast":61,"x_thread":26},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04608318\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"CLL17","nct_id":"NCT04608318","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=cll17-nct04608318. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"CLL17","arms":[{"description":"Ibrutinib p.o. will be administered until occurrence of unacceptable toxicity, progression of CLL or end of trial, whichever occurs first.","label":"I (Ibrutinib)","type":"EXPERIMENTAL"},{"description":"12 cycles (q 28d): Obinutuzumab i.v. + Venetoclax p.o. will be administered for 6 cycles, followed by 6 additional cycles of Venetoclax alone","label":"VG (Obinutuzumab + Venetoclax)","type":"EXPERIMENTAL"},{"description":"15 cycles (q 28d): Ibrutinib p.o. + Venetoclax p.o. will be administered for a total of 12 cycles with a prior Ibrutinib monotherapy lead-in of 3 cycles","label":"VI (Venetoclax + Ibrutinib)","type":"EXPERIMENTAL"}],"collaborators":["Stichting Hemato-Oncologie voor Volwassenen Nederland","Nordic CLL Study Group (NCLLSG)","Swiss Group for Clinical Cancer Research (SAKK)","Cancer Trials Ireland","Gruppo Italiano Malattie EMatologiche dell'Adulto","Grupo Español de Leucemia Linfocítica Crónica (GELLC)","The Israeli CLL Study Group (ICLLSG)","Janssen Pharmaceutica N.V., Belgium","AbbVie","Hoffmann-La Roche"],"completion_date":{"date":"2027-09","type":"ESTIMATED"},"conditions":["Chronic Lymphoid Leukemia"],"enrollment":{"count":897,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Ibrutinib","type":"BIOLOGICAL"},{"name":"Venetoclax","type":"BIOLOGICAL"},{"name":"Obinutuzumab","type":"BIOLOGICAL"}],"last_update":"2026-04-30","lead_sponsor":"German CLL Study Group","official_title":"A Phase 3 Multicentre, Randomized, Prospective, Open-label Trial of Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-09","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Investigator-assessed progression-free survival (PFS)","timeFrame":"Up to 80 month"}],"references":[{"citation":"Al-Sawaf O, Stumpf J, Zhang C, Simon F, Bosch F, Feyzi E, Ghia P, Gregor M, Kater AP, Lindstrom V, Mattsson M, Niemann CU, Staber PB, Tadmor T, Thornton P, Wendtner CM, Janssens A, Noesslinger T, Bohn JP, da Cunha-Bang C, Poulsen CB, Ranti J, Illmer T, Schoettker B, Bottcher S, Gaska T, Vandenberghe E, Clifford R, Benjamini O, Frustaci AM, Scarfo L, Sportoletti P, Schreurs J, Levin MD, van der Straaten H, van der Klift M, Tran H, de la Serna J, Loscertales J, Lindblad O, Bergendahl Sandstedt A, Goede J, Baumann M, Fink AM, Fischer K, Ritgen M, Kreuzer KA, Schneider C, Tausch E, Stilgenbauer S, Robrecht S, Eichhorst B, Hallek M; CLL17 Trial Investigators. Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia. N Engl J Med. 2026 Mar 12;394(11):1084-1096. doi: 10.1056/NEJMoa2515458. Epub 2025 Dec 6.","pmid":"41358601","type":"DERIVED"}],"start_date":{"date":"2021-03-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)","url":"https://clinicaltrials.gov/study/NCT04608318"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/cll17-nct04608318"}